[Federal Register Volume 81, Number 142 (Monday, July 25, 2016)]
[Notices]
[Page 48439]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-17419]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD, 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Novel metastatic serous epithelial ovarian 
cancer (SEOC) genetically engineered mouse models, cell lines, and 
orthotopic models based on Rb, p53 and/or Brca 1/2 inactivation useful 
for biomarker discovery and preclinical testing.
    Description of Technology: The high mortality rate from ovarian 
cancers can be attributed to late-stage diagnosis and lack of effective 
treatment. Despite enormous effort to develop better targeted 
therapies, platinum-based chemotherapy still remains the standard of 
care for ovarian cancer patients, and resistance occurs at a high rate. 
One of the rate limiting factors for translation of new drug 
discoveries into clinical treatments has been the lack of suitable 
preclinical cancer models with high predictive value.
    NCI CAPR has developed Tri-allelic K18-T121 tg/+ /Brca1 
fl/fl /p53 fl/fl SEOC GEM Model, GEM-derived SEOC 
orthotopic mouse model, and biological materials derived therefrom, 
with several key histopathologic, immunophenotypical, and genetic 
features of human SEOC. SEOC GEMs were utilized to create orthotopic 
immunocompetent transplant models, and to generate synchronized cohorts 
of mice suitable for preclinical studies. NCI CAPR conducted studies 
that determine these models are tractable for use in routine efficacy 
studies and demonstrate the utility of these models in evaluating the 
potential efficacy of novel therapeutics for ovarian cancer.
    Potential Commercial Applications:
     These models serve as a foundation for preclinical 
research and evaluation of efficacy of novel therapeutics for ovarian 
cancer.
     The GEM models described here can be used to develop cell 
lines and allograft models for evaluating drug potency relative to 
Brca1 mutation status.
     These mouse models provide the opportunity for evaluation 
of effective therapeutics, including prediction of differential 
responses in Brca1-wild type and Brca1-deficient tumors and development 
of relevant biomarkers.
    Value Proposition:
     Novel resource for evaluating disease etiology and 
biomarkers, therapeutic evaluation, and improved imaging strategies in 
epithelial ovarian cancer
     Similarity to human ovarian cancer based on 
transcriptional profiling
     Suitable preclinical cancer models with high predictive 
value.
    Development Stage: Pre-clinical (in vivo validation).
    Inventor(s): Simone Difilippantonio, Terry Van Dyke, Zoe Weaver 
Ohler, Ludmila Szabova, Sujata Bupp, Yurong Song, Chaoying Yin.
    Intellectual Property: Research use--no patent protection will be 
sought.
    Publications:

1. Szabova L., Yin C., Bupp S., et al. Perturbation of Rb, p53 and 
Brca1 or Brca2 cooperate in inducing metastatic serous epithelial 
ovarian cancer. Cancer research. 2012;72(16):4141-4153.
2. Szabova L., Bupp S., Kamal M., et al. Pathway-Specific Engineered 
Mouse Allograft Models Functionally Recapitulate Human Serous 
Epithelial Ovarian Cancer. Katoh M., ed. PLoS ONE. 2014;9(4):e95649.

    Collaboration Opportunity: Researchers at the NCI seek licensing 
and/or co-development research collaborations for the commercialization 
of agents for the treatment of SEOC.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].

    Dated: July 11, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-17419 Filed 7-22-16; 8:45 am]
BILLING CODE 4140-01-P